Concord Drugs
BSE: CONCORD · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Concord Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Concord Drugs Limited is a Hyderabad-based pharmaceutical company specialising in the manufacturing of bulk drugs and finished formulations. The firm focuses on niche drug delivery systems, particularly sustained-release and enteric-coated pellets produced via advanced fluid bed technology.
Business Model
The company generates revenue through the production and sale of therapeutic products including anti-ulcerants, anti-fungals, and anti-hypertensives. It leverages Good Manufacturing Practices to supply both domestic and international pharmaceutical markets.
Growth Outlook
Growth is driven by the company's commitment to research and development in new drug delivery mechanisms designed to improve the efficacy of existing medications. Continued adherence to international manufacturing standards supports its expansion into global markets.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining stringent Good Manufacturing Practices required for domestic and international pharmaceutical approvals.
- Market Competition. The pharmaceutical sector is highly competitive, potentially impacting margins for bulk drugs and generic formulations.
- R&D Uncertainty. Investments in new drug delivery mechanisms carry inherent risks regarding successful development and commercialisation.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can adversely affect manufacturing costs.
Start your research today
Unlock AI insights, financials, peers and live data on Concord Drugs and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Concord DrugsCONCORD | ₹107 Cr | — | — | — | 35.0% | — | — | +30.7% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Concord Drugs
BSE: CONCORD · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Concord Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Concord Drugs Limited is a Hyderabad-based pharmaceutical company specialising in the manufacturing of bulk drugs and finished formulations. The firm focuses on niche drug delivery systems, particularly sustained-release and enteric-coated pellets produced via advanced fluid bed technology.
Business Model
The company generates revenue through the production and sale of therapeutic products including anti-ulcerants, anti-fungals, and anti-hypertensives. It leverages Good Manufacturing Practices to supply both domestic and international pharmaceutical markets.
Growth Outlook
Growth is driven by the company's commitment to research and development in new drug delivery mechanisms designed to improve the efficacy of existing medications. Continued adherence to international manufacturing standards supports its expansion into global markets.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining stringent Good Manufacturing Practices required for domestic and international pharmaceutical approvals.
- Market Competition. The pharmaceutical sector is highly competitive, potentially impacting margins for bulk drugs and generic formulations.
- R&D Uncertainty. Investments in new drug delivery mechanisms carry inherent risks regarding successful development and commercialisation.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can adversely affect manufacturing costs.
Start your research today
Unlock AI insights, financials, peers and live data on Concord Drugs and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026